Youle 2000.

Methods	N=35 Non randomized W/o: unclear Follow up: unclear
Participants	Eligibility:‐ VL>50,000 RNA cop/ml, ART: on PI based 4 drug regimen for 6 months, Pre STI ART duration: >4.4 years Baseline CD4 125 (36‐254) Baseline VL 540,000 (72,000‐750,000)
Interventions	TI 1‐2 months Washout period present
Outcomes	CD4 differences b/w control and STI gps: 0‐4 months:85 cells/mm3 ( p<0.001) 5‐8 months: 47 cells/mm3 (p<0.001) 9‐20 months: 31 cells/mm3 (p<0.11) Control group mean CD4 counts higher by 85 cells p<0.001 VL differences b/w STI and Control gps: 0‐4 months: +1.2 log cop/ml higher in STI gp (p<0.001), 4‐20 months: 0.8 log cop/ml suppressed both gps Viral reversion: 64% pts A/E: no difference between gps Death: 8 pts both gps (HR=2.57(1.2‐5.5) (p=0.01) Disease events: 17 pts STI gp 5 pts control gp HR=6.04(1.8‐20.8) Quality of life at 2 months: STI gp: SF12 score +1.7 Control gp: SF12 score ‐0.4
Notes	1.Greater loss of CD4 soon after interruption (p=0.03). 2. Faster decline in CD4 within the first three weeks.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	D ‐ Not used